APO Research
Talk to an analyst

APO RESEARCH · REPORT

Veterinary Infectious Diseases Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Veterinary Infectious Diseases Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchVeterinary Infectious Diseases Therapeutics Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Veterinary Infectious Diseases Therapeutics Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Veterinary Infectious Diseases Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Veterinary Infectious Diseases Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Veterinary Infectious Diseases Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Veterinary Infectious Diseases Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Veterinary Infectious Diseases Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Veterinary Infectious Diseases Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Veterinary Infectious Diseases Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Veterinary Infectious Diseases Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Veterinary Infectious Diseases Therapeutics market include Sanofi, Merck, Virbac, Pfizer Animal Health, Novartis Animal Health, Elanco Animal Health, Elanco Animal Health, Dechra Animal Health and Ceva Sante Animale, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Veterinary Infectious Diseases Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Veterinary Infectious Diseases Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Veterinary Infectious Diseases Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Veterinary Infectious Diseases Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Veterinary Infectious Diseases Therapeutics Segment by Company

Sanofi

Merck

Virbac

Pfizer Animal Health

Novartis Animal Health

Elanco Animal Health

Elanco Animal Health

Dechra Animal Health

Ceva Sante Animale

Boehringer Ingelheim Vetmedica

Veterinary Infectious Diseases Therapeutics Segment by Type

Amebicides

Anthelmintics

Antifungal

Antibiotics

Antiviral

Veterinary Infectious Diseases Therapeutics Segment by Application

Swine

Cow

Cat

Horse

Chicken

Dog

Other

Veterinary Infectious Diseases Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Veterinary Infectious Diseases Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Veterinary Infectious Diseases Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Veterinary Infectious Diseases Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Veterinary Infectious Diseases Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Infectious Diseases Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Veterinary Infectious Diseases Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Infectious Diseases Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Veterinary Infectious Diseases Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Veterinary Infectious Diseases Therapeutics industry.

Chapter 3: Detailed analysis of Veterinary Infectious Diseases Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Veterinary Infectious Diseases Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Veterinary Infectious Diseases Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Veterinary Infectious Diseases Therapeutics Industry Trends Table 2. Veterinary Infectious Diseases Therapeutics Industry Drivers Table 3. Veterinary Infectious Diseases Therapeutics Industry Opportunities and Challenges Table 4. Veterinary Infectious Diseases Therapeutics Industry Restraints Table 5. Global Veterinary Infectious Diseases Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Veterinary Infectious Diseases Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Company (kg) & (2021-2026) Table 8. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Veterinary Infectious Diseases Therapeutics Average Price (US$/kg) of Company (2021-2026) Table 10. Global Veterinary Infectious Diseases Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Veterinary Infectious Diseases Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Veterinary Infectious Diseases Therapeutics Company, Product Type & Application Table 13. Global Veterinary Infectious Diseases Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Veterinary Infectious Diseases Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Amebicides Table 18. Significant Companies of Anthelmintics Table 19. Significant Companies of Antifungal Table 20. Significant Companies of Antibiotics Table 21. Significant Companies of Antiviral Table 22. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (kg) Table 23. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Type (2021-2026) & (kg) Table 24. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Type (2027-2032) & (kg) Table 25. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Type (2021-2026) Table 26. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Type (2027-2032) Table 27. Global Veterinary Infectious Diseases Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Veterinary Infectious Diseases Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Veterinary Infectious Diseases Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Type (2021-2026) Table 31. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Swine Table 33. Significant Companies of Cow Table 34. Significant Companies of Cat Table 35. Significant Companies of Horse Table 36. Significant Companies of Chicken Table 37. Significant Companies of Dog Table 38. Significant Companies of Other Table 39. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (kg) Table 40. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Application (2021-2026) & (kg) Table 41. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Application (2027-2032) & (kg) Table 42. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Application (2021-2026) Table 43. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Application (2027-2032) Table 44. Global Veterinary Infectious Diseases Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Veterinary Infectious Diseases Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Veterinary Infectious Diseases Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Application (2021-2026) Table 48. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Application (2027-2032) Table 49. Global Veterinary Infectious Diseases Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (kg) Table 50. Global Veterinary Infectious Diseases Therapeutics Sales by Region (2021-2026) & (kg) Table 51. Global Veterinary Infectious Diseases Therapeutics Sales Market Share by Region (2021-2026) Table 52. Global Veterinary Infectious Diseases Therapeutics Sales by Region (2027-2032) & (kg) Table 53. Global Veterinary Infectious Diseases Therapeutics Sales Market Share by Region (2027-2032) Table 54. Global Veterinary Infectious Diseases Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Veterinary Infectious Diseases Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Region (2021-2026) Table 57. Global Veterinary Infectious Diseases Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Region (2027-2032) Table 59. Global Veterinary Infectious Diseases Therapeutics Market Average Price (US$/kg) by Region (2021-2026) Table 60. Global Veterinary Infectious Diseases Therapeutics Market Average Price (US$/kg) by Region (2027-2032) Table 61. Global Veterinary Infectious Diseases Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (kg) Table 62. Global Veterinary Infectious Diseases Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Veterinary Infectious Diseases Therapeutics Sales by Country (2021-2026) & (kg) Table 64. Global Veterinary Infectious Diseases Therapeutics Sales Market Share by Country (2021-2026) Table 65. Global Veterinary Infectious Diseases Therapeutics Sales by Country (2027-2032) & (kg) Table 66. Global Veterinary Infectious Diseases Therapeutics Sales Market Share by Country (2027-2032) Table 67. Global Veterinary Infectious Diseases Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Veterinary Infectious Diseases Therapeutics Sales Value Market Share by Country (2021-2026) Table 69. Global Veterinary Infectious Diseases Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Veterinary Infectious Diseases Therapeutics Sales Value Market Share by Country (2027-2032) Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 74. Sanofi Veterinary Infectious Diseases Therapeutics Product Portfolio Table 75. Sanofi Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 79. Merck Veterinary Infectious Diseases Therapeutics Product Portfolio Table 80. Merck Recent Development Table 81. Virbac Company Information Table 82. Virbac Business Overview Table 83. Virbac Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 84. Virbac Veterinary Infectious Diseases Therapeutics Product Portfolio Table 85. Virbac Recent Development Table 86. Pfizer Animal Health Company Information Table 87. Pfizer Animal Health Business Overview Table 88. Pfizer Animal Health Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 89. Pfizer Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio Table 90. Pfizer Animal Health Recent Development Table 91. Novartis Animal Health Company Information Table 92. Novartis Animal Health Business Overview Table 93. Novartis Animal Health Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 94. Novartis Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio Table 95. Novartis Animal Health Recent Development Table 96. Elanco Animal Health Company Information Table 97. Elanco Animal Health Business Overview Table 98. Elanco Animal Health Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 99. Elanco Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio Table 100. Elanco Animal Health Recent Development Table 101. Elanco Animal Health Company Information Table 102. Elanco Animal Health Business Overview Table 103. Elanco Animal Health Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 104. Elanco Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio Table 105. Elanco Animal Health Recent Development Table 106. Dechra Animal Health Company Information Table 107. Dechra Animal Health Business Overview Table 108. Dechra Animal Health Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 109. Dechra Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio Table 110. Dechra Animal Health Recent Development Table 111. Ceva Sante Animale Company Information Table 112. Ceva Sante Animale Business Overview Table 113. Ceva Sante Animale Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 114. Ceva Sante Animale Veterinary Infectious Diseases Therapeutics Product Portfolio Table 115. Ceva Sante Animale Recent Development Table 116. Boehringer Ingelheim Vetmedica Company Information Table 117. Boehringer Ingelheim Vetmedica Business Overview Table 118. Boehringer Ingelheim Vetmedica Veterinary Infectious Diseases Therapeutics Sales (kg), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 119. Boehringer Ingelheim Vetmedica Veterinary Infectious Diseases Therapeutics Product Portfolio Table 120. Boehringer Ingelheim Vetmedica Recent Development Table 121. Key Raw Materials Table 122. Raw Materials Key Suppliers Table 123. Veterinary Infectious Diseases Therapeutics Distributors List Table 124. Veterinary Infectious Diseases Therapeutics Customers List Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Veterinary Infectious Diseases Therapeutics Product Image Figure 2. Global Veterinary Infectious Diseases Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Veterinary Infectious Diseases Therapeutics Sales (2021-2032) & (kg) Figure 5. Global Veterinary Infectious Diseases Therapeutics Sales Average Price (US$/kg) & (2021-2032) Figure 6. Global Veterinary Infectious Diseases Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Amebicides Image Figure 10. Anthelmintics Image Figure 11. Antifungal Image Figure 12. Antibiotics Image Figure 13. Antiviral Image Figure 14. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (kg) Figure 15. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Type (2021-2032) Figure 17. Global Veterinary Infectious Diseases Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Veterinary Infectious Diseases Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Type (2021-2032) Figure 20. Swine Image Figure 21. Cow Image Figure 22. Cat Image Figure 23. Horse Image Figure 24. Chicken Image Figure 25. Dog Image Figure 26. Other Image Figure 27. Global Veterinary Infectious Diseases Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (kg) Figure 28. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Application (2021-2032) Figure 30. Global Veterinary Infectious Diseases Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Veterinary Infectious Diseases Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Application (2021-2032) Figure 33. Global Veterinary Infectious Diseases Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (kg) Figure 34. Global Veterinary Infectious Diseases Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Veterinary Infectious Diseases Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 38. North America Veterinary Infectious Diseases Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Veterinary Infectious Diseases Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Veterinary Infectious Diseases Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 44. South America Veterinary Infectious Diseases Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Veterinary Infectious Diseases Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Veterinary Infectious Diseases Therapeutics Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Veterinary Infectious Diseases Therapeutics Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Amebicides
  • Anthelmintics
  • Antifungal
  • Antibiotics
  • Antiviral
Applications
  • Swine
  • Cow
  • Cat
  • Horse
  • Chicken
  • Dog
  • Other
Companies covered
  • Sanofi
  • Merck
  • Virbac
  • Pfizer Animal Health
  • Novartis Animal Health
  • Elanco Animal Health
  • Elanco Animal Health
  • Dechra Animal Health
  • Ceva Sante Animale
  • Boehringer Ingelheim Vetmedica

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Veterinary Infectious Diseases Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Veterinary Infectious Diseases Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Veterinary Infectious Diseases Therapeutics Market Dynamics
  1. 2.1 Veterinary Infectious Diseases Therapeutics Industry Trends
  2. 2.2 Veterinary Infectious Diseases Therapeutics Industry Drivers
  3. 2.3 Veterinary Infectious Diseases Therapeutics Industry Opportunities and Challenges
  4. 2.4 Veterinary Infectious Diseases Therapeutics Industry Restraints
3 Veterinary Infectious Diseases Therapeutics Market by Company
  1. 3.1 Global Veterinary Infectious Diseases Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Veterinary Infectious Diseases Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Veterinary Infectious Diseases Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Veterinary Infectious Diseases Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Veterinary Infectious Diseases Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Veterinary Infectious Diseases Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Veterinary Infectious Diseases Therapeutics Company Product Type and Application
  8. 3.8 Global Veterinary Infectious Diseases Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Veterinary Infectious Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Veterinary Infectious Diseases Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Veterinary Infectious Diseases Therapeutics Market by Type
  1. 4.1 Veterinary Infectious Diseases Therapeutics Type Introduction
  2. 4.1.1 Amebicides
  3. 4.1.2 Anthelmintics
  4. 4.1.3 Antifungal
  5. 4.1.4 Antibiotics
  6. 4.1.5 Antiviral
  7. 4.2 Global Veterinary Infectious Diseases Therapeutics Sales Volume by Type
  8. 4.2.1 Global Veterinary Infectious Diseases Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Veterinary Infectious Diseases Therapeutics Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Veterinary Infectious Diseases Therapeutics Sales Value by Type
  12. 4.3.1 Global Veterinary Infectious Diseases Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Veterinary Infectious Diseases Therapeutics Sales Value by Type (2021-2032)
  14. 4.3.3 Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Type (2021-2032)
5 Veterinary Infectious Diseases Therapeutics Market by Application
  1. 5.1 Veterinary Infectious Diseases Therapeutics Application Introduction
  2. 5.1.1 Swine
  3. 5.1.2 Cow
  4. 5.1.3 Cat
  5. 5.1.4 Horse
  6. 5.1.5 Chicken
  7. 5.1.6 Dog
  8. 5.1.7 Other
  9. 5.2 Global Veterinary Infectious Diseases Therapeutics Sales Volume by Application
  10. 5.2.1 Global Veterinary Infectious Diseases Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Veterinary Infectious Diseases Therapeutics Sales Volume by Application (2021-2032)
  12. 5.2.3 Global Veterinary Infectious Diseases Therapeutics Sales Volume Share by Application (2021-2032)
  13. 5.3 Global Veterinary Infectious Diseases Therapeutics Sales Value by Application
  14. 5.3.1 Global Veterinary Infectious Diseases Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  15. 5.3.2 Global Veterinary Infectious Diseases Therapeutics Sales Value by Application (2021-2032)
  16. 5.3.3 Global Veterinary Infectious Diseases Therapeutics Sales Value Share by Application (2021-2032)
6 Veterinary Infectious Diseases Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Veterinary Infectious Diseases Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Veterinary Infectious Diseases Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Veterinary Infectious Diseases Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Veterinary Infectious Diseases Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Veterinary Infectious Diseases Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Veterinary Infectious Diseases Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Veterinary Infectious Diseases Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Veterinary Infectious Diseases Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Veterinary Infectious Diseases Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Veterinary Infectious Diseases Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Veterinary Infectious Diseases Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Veterinary Infectious Diseases Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Veterinary Infectious Diseases Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Veterinary Infectious Diseases Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Veterinary Infectious Diseases Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Veterinary Infectious Diseases Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Veterinary Infectious Diseases Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Veterinary Infectious Diseases Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Veterinary Infectious Diseases Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Veterinary Infectious Diseases Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Veterinary Infectious Diseases Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Veterinary Infectious Diseases Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Veterinary Infectious Diseases Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Veterinary Infectious Diseases Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Veterinary Infectious Diseases Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Veterinary Infectious Diseases Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Veterinary Infectious Diseases Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Veterinary Infectious Diseases Therapeutics Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Veterinary Infectious Diseases Therapeutics Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Virbac
  14. 8.3.1 Virbac Company Information
  15. 8.3.2 Virbac Business Overview
  16. 8.3.3 Virbac Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Virbac Veterinary Infectious Diseases Therapeutics Product Portfolio
  18. 8.3.5 Virbac Recent Developments
  19. 8.4 Pfizer Animal Health
  20. 8.4.1 Pfizer Animal Health Company Information
  21. 8.4.2 Pfizer Animal Health Business Overview
  22. 8.4.3 Pfizer Animal Health Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
  24. 8.4.5 Pfizer Animal Health Recent Developments
  25. 8.5 Novartis Animal Health
  26. 8.5.1 Novartis Animal Health Company Information
  27. 8.5.2 Novartis Animal Health Business Overview
  28. 8.5.3 Novartis Animal Health Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
  30. 8.5.5 Novartis Animal Health Recent Developments
  31. 8.6 Elanco Animal Health
  32. 8.6.1 Elanco Animal Health Company Information
  33. 8.6.2 Elanco Animal Health Business Overview
  34. 8.6.3 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
  36. 8.6.5 Elanco Animal Health Recent Developments
  37. 8.7 Elanco Animal Health
  38. 8.7.1 Elanco Animal Health Company Information
  39. 8.7.2 Elanco Animal Health Business Overview
  40. 8.7.3 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
  42. 8.7.5 Elanco Animal Health Recent Developments
  43. 8.8 Dechra Animal Health
  44. 8.8.1 Dechra Animal Health Company Information
  45. 8.8.2 Dechra Animal Health Business Overview
  46. 8.8.3 Dechra Animal Health Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Dechra Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
  48. 8.8.5 Dechra Animal Health Recent Developments
  49. 8.9 Ceva Sante Animale
  50. 8.9.1 Ceva Sante Animale Company Information
  51. 8.9.2 Ceva Sante Animale Business Overview
  52. 8.9.3 Ceva Sante Animale Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ceva Sante Animale Veterinary Infectious Diseases Therapeutics Product Portfolio
  54. 8.9.5 Ceva Sante Animale Recent Developments
  55. 8.10 Boehringer Ingelheim Vetmedica
  56. 8.10.1 Boehringer Ingelheim Vetmedica Company Information
  57. 8.10.2 Boehringer Ingelheim Vetmedica Business Overview
  58. 8.10.3 Boehringer Ingelheim Vetmedica Veterinary Infectious Diseases Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Vetmedica Veterinary Infectious Diseases Therapeutics Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Vetmedica Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Veterinary Infectious Diseases Therapeutics Value Chain Analysis
  2. 9.1.1 Veterinary Infectious Diseases Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Veterinary Infectious Diseases Therapeutics Sales Mode & Process
  6. 9.2 Veterinary Infectious Diseases Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Veterinary Infectious Diseases Therapeutics Distributors
  9. 9.2.3 Veterinary Infectious Diseases Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst